Adapting Body Reprogramming for severe asthma: a feasibility study
Research type
Research Study
Full title
Body reprogramming as an adjunct to biologic administration in patients with Severe Asthma: a feasibility study
IRAS ID
285153
Contact name
Matthew Masoli
Contact email
Sponsor organisation
Royal Devon and Exeter Hospitals NHS Trust
Duration of Study in the UK
1 years, 2 months, 31 days
Research summary
There are many symptoms associated with severe asthma, not all of them related to the lung. These are referred to as extra-pulmonary symptoms and their relationship with quality of life is complex.
Body reprogramming (BR) is a non-drug intervention originally developed for fibromyalgia patients with the aim of improving health and wellbeing in a personalised way, with evidence-based lifestyle changes. The frequency and severity of multiple symptoms in severe asthma is similar to fibromyalgia and we therefore propose that BR may be a suitable non-drug intervention for severe asthma patients who are about to step up drug treatment.
Our study aims are therefore to assess how BR may be suitable for people with severe asthma, and to adapt and optimise the programme for these people. In two phases, severe asthma patients will be recruited via a regional severe asthma clinic at the Royal Devon & Exeter NHS Trust and invited to take part in a short course of BR. In phase one, patients will be asked to attend four weekly researcher-led sessions of BR via video call and be given practice tasks to report on at the subsequent session. Questionnaires will be completed for the first and last session, as well as at 12 and 36 weeks following BR. At the end of BR, patients will also be invited to take part in a focus group. The data collected will inform development of the programme for phase two, which will involve recruitment of severe asthma patient who are about to start biologic drug treatment for their severe asthma. The total length of the study is 15 months.
This study has been funded by GlaxoSmithKline.REC name
Wales REC 2
REC reference
21/WA/0159
Date of REC Opinion
17 May 2021
REC opinion
Favourable Opinion